Stock listing

NASDAQ:TCRX TScan Therapeutics, Inc. Stock

Home listing (NASDAQ) of TScan Therapeutics, Inc.

Follow TScan Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:TCRX

$0.21 USD -0.02 (-9.0%)

Close on Oct 19, 2026

Past 3 months -80.0% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
$0.21 – $0.238 USDOct 19, 2026
Volume
364,123 sharesOct 19, 2026
Market cap
$13.74M USDAt the close on Oct 19, 2026 · price × 65.35M shares outstanding
TScan Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:TCRX · Home$0.21 USD-0.021 (-9.0%)364,123$0.238$0.238$0.21$0.231Close on Oct 19, 2026

Daily closes

Last 3 months, Jul 20, 2026 – Oct 19, 2026 · NASDAQ:TCRX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.21-0.021-9.0%$0.238$0.238$0.21364,123
$0.231-0.008-3.5%$0.238$0.245$0.23568,221
$0.239+0.029+13.6%$0.216$0.243$0.209878,271
$0.211-0.006-2.8%$0.224$0.228$0.201546,576
$0.217-0.021-8.9%$0.24$0.24$0.212456,372
$0.2380.000.0%$0.24$0.249$0.23483,537
$0.238+0.01+4.3%$0.228$0.247$0.228873,346
$0.228-0.049-17.6%$0.271$0.273$0.2241,534,641
$0.277+0.002+0.7%$0.271$0.283$0.263542,100
$0.275-0.02-6.8%$0.293$0.296$0.264601,900
$0.295-0.026-8.1%$0.317$0.33$0.285749,900
$0.321+0.003+0.9%$0.33$0.33$0.316144,400
$0.318+0.003+1.0%$0.319$0.329$0.311622,700
$0.315-0.003-0.9%$0.322$0.345$0.315554,400
$0.318-0.022-6.5%$0.339$0.346$0.311753,200
$0.340.000.0%$0.34$0.348$0.325359,200
$0.34-0.009-2.6%$0.352$0.37$0.33381,900
$0.349-0.015-4.1%$0.369$0.369$0.34606,700
$0.364+0.009+2.5%$0.36$0.372$0.3411,081,000
$0.355+0.024+7.3%$0.333$0.36$0.33918,500
$0.331+0.019+6.1%$0.311$0.342$0.311752,900
$0.312-0.022-6.6%$0.343$0.357$0.311,143,200
$0.334+0.003+0.9%$0.335$0.362$0.3241,096,300
$0.331+0.01+3.1%$0.33$0.34$0.321883,900
$0.321+0.015+4.9%$0.316$0.322$0.29677,200
$0.306-0.014-4.4%$0.32$0.334$0.3061,104,000
$0.32+0.002+0.6%$0.324$0.325$0.306873,100
$0.318-0.012-3.6%$0.32$0.35$0.31804,600
$0.33-0.015-4.3%$0.34$0.343$0.33704,200
$0.345-0.047-12.0%$0.38$0.38$0.331,536,300
$0.392+0.021+5.7%$0.37$0.417$0.3651,674,000
$0.371-0.01-2.6%$0.381$0.402$0.3513,091,000
$0.381-0.285-42.8%$0.55$0.57$0.368,517,400
$0.666-0.064-8.8%$0.723$0.77$0.656820,300
$0.73-0.024-3.2%$0.75$0.766$0.721330,100
$0.754+0.004+0.5%$0.755$0.78$0.75150,700
$0.75-0.027-3.5%$0.777$0.80$0.747287,800
$0.777-0.017-2.1%$0.778$0.792$0.77468,300
$0.794-0.005-0.6%$0.792$0.811$0.777180,600
$0.799+0.019+2.4%$0.79$0.80$0.768194,400
$0.78+0.004+0.5%$0.79$0.79$0.772136,200
$0.776+0.026+3.5%$0.75$0.789$0.75338,300
$0.75-0.075-9.1%$0.77$0.825$0.75580,100
$0.825+0.041+5.2%$0.77$0.838$0.77173,500
$0.784+0.005+0.6%$0.78$0.795$0.763352,800
$0.779+0.007+0.9%$0.768$0.789$0.741278,400
$0.772-0.001-0.1%$0.779$0.79$0.764297,600
$0.773-0.004-0.5%$0.791$0.791$0.751528,000
$0.777+0.01+1.3%$0.772$0.799$0.764248,100
$0.767-0.029-3.6%$0.80$0.80$0.762464,300
$0.796+0.033+4.3%$0.754$0.804$0.754336,300
$0.763-0.017-2.2%$0.771$0.781$0.75129,800
$0.78+0.043+5.8%$0.745$0.78$0.745298,600
$0.737+0.014+1.9%$0.716$0.758$0.716796,200
$0.723-0.02-2.7%$0.759$0.78$0.72441,400
$0.743-0.013-1.7%$0.78$0.78$0.73253,900
$0.756+0.014+1.9%$0.756$0.779$0.74430,300
$0.742-0.032-4.1%$0.775$0.798$0.733609,500
$0.774+0.006+0.8%$0.765$0.774$0.732717,300
$0.768-0.026-3.3%$0.809$0.87$0.76907,000
$0.794-0.052-6.1%$0.87$0.892$0.791,063,100
$0.846-0.054-6.0%$0.88$0.922$0.8461,082,200
$0.90-0.04-4.3%$0.94$0.957$0.90496,300
$0.94+0.015+1.6%$0.925$0.95$0.908145,700
$0.925+0.01+1.1%$0.937$0.97$0.89299,500
Ticker
NASDAQ:TCRX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

Sep 2, 2026

Closed $0.381 (-42.8%) on Sep 2, 2026

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 12, 2026

Closed $0.773 (-0.5%) on Aug 12, 2026

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

Jul 30, 2026

Closed $0.756 (+1.9%) on Jul 30, 2026

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Jun 24, 2026

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

Jun 22, 2026

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

Jun 3, 2026

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 6, 2026

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

Apr 27, 2026

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 4, 2026

All TScan Therapeutics, Inc. news

Decks

TScan Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
18 in the last 12 months · 99 in all · newest Sep 2, 2026 · oldest 2021
Decks
10 decks · latest Sep 2, 2026

Where TScan Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:TCRX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:TCRXBOATSUnited StatesUSD

Log in to ask 6ix AI your own questions about TScan Therapeutics, Inc.